Drug intelligence / Profile preview

MUC-1 vaccine

Development stage: Preclinical
Lead developer: GeoVax Labs
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

GeoVax's MUC-1 vaccine is a cancer immunotherapy developed by GeoVax Labs, utilizing its Modified Vaccinia Ankara (MVA) - Virus-Like Particle (VLP) platform. This vaccine is being investigated for its potential in cancer treatment, specifically in combination with novel PD-1 checkpoint inhibitors. Preclinical studies conducted in humanized mice have demonstrated its efficacy in significantly reducing existing tumors and preventing the growth of new tumors.

Other names: GeoVax's MUC-1 vaccine

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on MUC-1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MUC-1 vaccine.

Explore the full profile